UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics is the firm’s top pick in Specialty Pharma in 2025, and while the price target reduction reflects the modest Winrevair impact to Tyvaso, the firm remains Buy-rated due to idiopathic pulmonary fibrosis read-outs starting in the second half of 2025 onwards and progress on xenotransplantation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics: TETON 1 study of nebulized Tyvaso for IPF fully enrolled
- United Therapeutics announces FDA clearance of UKidney NDA
- United Therapeutics to Present at J.P. Morgan Conference
- Trump Trade: New administration to invest $20B to build data centers
- United Therapeutics price target raised to $475 from $415 at UBS